» Articles » PMID: 36680147

The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 Jan 21
PMID 36680147
Authors
Affiliations
Soon will be listed here.
Abstract

HIV/AIDS mortality has been decreasing over the last decade. While promising, this decrease correlated directly with increased use of antiretroviral drugs. As a natural consequence of its high mutation rate, treatments provide selection pressure that promotes the natural selection of escape mutants. Individuals may acquire drug-naive strains, or those that have already mutated due to treatment. Even within a host, mutation affects HIV tropism, where initial infection begins with R5-tropic virus, but the clinical transition to AIDS correlates with mutations that lead to an X4-tropic switch. Furthermore, the high mutation rate of HIV has spelled failure for all attempts at an effective vaccine. Pre-exposure drugs are currently the most effective drug-based preventatives, but their effectiveness is also threatened by viral mutation. From attachment and entry to assembly and release, the steps in the replication cycle are also discussed to describe the drug mechanisms and mutations that arise due to those drugs. Revealing the patterns of HIV-1 mutations, their effects, and the coordinated attempt to understand and control them will lead to effective use of current preventative measures and treatment options, as well as the development of new ones.

Citing Articles

Low prevalence of HIV in the northern Cameroon: contribution of some AIDS restriction genes and potential implications for gene therapy.

Djataou P, Djuidje Ngounoue M, Nkenfou-Tchinda C, Ngoufack M, Elong E, Tiga A Front Genet. 2024; 15:1447971.

PMID: 39346778 PMC: 11427317. DOI: 10.3389/fgene.2024.1447971.


Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation.

Mimtsoudis I, Tsachouridou O, Akinosoglou K, Metallidis S Viruses. 2024; 16(9).

PMID: 39339868 PMC: 11437411. DOI: 10.3390/v16091392.


CCR5 Decorated Rilpivirine Lipid Nanoparticles Build Myeloid Drug Depots Which Sustains Antiretroviral Activities.

Gendelman H, Patel M, Panja S, Zaman L, Yeapuri P, Bhattarai S Res Sq. 2024; .

PMID: 38883780 PMC: 11177988. DOI: 10.21203/rs.3.rs-4433306/v1.


Navigating the Antiretroviral Therapy Switch Conundrum: Unveiling the Dilemma of Drug Resistance and Disease Progression in HIV/AIDS.

Sharma A, Vardhan G, Dhamija P, Kumar V Cureus. 2024; 16(3):e56441.

PMID: 38638795 PMC: 11024777. DOI: 10.7759/cureus.56441.


High-resolution Inference of Multiplexed Anti-HIV Gene Editing using Single-Cell Targeted DNA Sequencing.

Bouzidi M, Dossani Z, Di Benedetto C, Raymond K, Desai S, Chavez L bioRxiv. 2024; .

PMID: 38328062 PMC: 10849705. DOI: 10.1101/2024.01.24.576921.


References
1.
Gray G, Allen M, Moodie Z, Churchyard G, Bekker L, Nchabeleng M . Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7):507-15. PMC: 3417349. DOI: 10.1016/S1473-3099(11)70098-6. View

2.
Van Duyne R, Kuo L, Pham P, Fujii K, Freed E . Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle. Proc Natl Acad Sci U S A. 2019; 116(18):9040-9049. PMC: 6500141. DOI: 10.1073/pnas.1820333116. View

3.
Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V . Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. mBio. 2017; 8(5). PMC: 5615196. DOI: 10.1128/mBio.00922-17. View

4.
Dyda F, Hickman A, Jenkins T, Engelman A, Craigie R, Davies D . Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science. 1994; 266(5193):1981-6. DOI: 10.1126/science.7801124. View

5.
McGovern R, Symons J, Poon A, Harrigan P, Van Lelyveld S, Hoepelman A . Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint. J Antimicrob Chemother. 2013; 68(9):2007-14. DOI: 10.1093/jac/dkt153. View